<DOC>
	<DOC>NCT00501605</DOC>
	<brief_summary>Single centre recruiting approximately 80 patients who are given a rising single, followed by multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in patients with solid tumors and metastatic liver disease.</brief_summary>
	<brief_title>Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Provision of written informed consent Male/female, 18 yr or over WHO status 02 Refractory advanced solid tumor Radiotherapy within 4 weeks of starting AZD2171 treatment Low haemoglobin level Low platelet or neutrophil counts</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Phase I</keyword>
	<keyword>AZD2171</keyword>
	<keyword>advanced solid tumors</keyword>
</DOC>